Aurinia CEO Emphasizes LUPKYNIS as Standard Treatment for Lupus Nephritis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy AUPH?
"Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases," stated Kevin Tang, Chief Executive Officer. "LUPKYNIS is emerging as a standard-of-care treatment for lupus nephritis, and aritinercept, now in clinical development for three potential indications, has therapeutic potential across a wide range of autoimmune disorders."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AUPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AUPH
Wall Street analysts forecast AUPH stock price to rise
6 Analyst Rating
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 15.230
Low
13.00
Averages
16.50
High
21.00
Current: 15.230
Low
13.00
Averages
16.50
High
21.00
About AUPH
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aurinia Reports 23% Revenue Growth in Q1
- Revenue Growth Highlight: Aurinia reported first-quarter revenue of $77.7 million, a 24% year-over-year increase that surpassed Wall Street's expectations of $77 million, indicating strong market performance despite a stock price drop due to information scarcity.
- Lupkynis Sales Surge: The 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, was the primary driver of revenue growth, reflecting robust market demand for this critical therapy.
- Leadership Change Impact: Following a significant leadership overhaul in March, with Kevin Tang appointed as CEO, investor unease grew due to the absence of an earnings call and limited updates on clinical trials, resulting in a more than 10% drop in stock price in a single day despite positive earnings.
- Future Outlook: The company reiterated its FY2026 revenue guidance of $315 million to $325 million, representing an 11% to 15% year-over-year growth, demonstrating confidence in future growth prospects despite market volatility.
See More
Aurinia Pharmaceuticals Reports Q1 Earnings Growth
- Earnings Growth: Aurinia Pharmaceuticals reported a first-quarter net income of $34.36 million, translating to an EPS of $0.25, which marks a significant increase from last year's $23.34 million and $0.16 EPS, indicating strong market performance.
- Revenue Increase: The company's revenue for the quarter reached $77.71 million, up 24.4% from $62.47 million last year, driven primarily by increased market acceptance of new products, reinforcing its position in the biopharmaceutical sector.
- Full-Year Guidance: Aurinia has provided a full-year revenue guidance of $315 million to $325 million, reflecting confidence in future market demand and potentially attracting more investor interest.
- Market Reaction: With the improved earnings and positive outlook guidance, Aurinia's stock is likely to gain favor among investors, further enhancing its competitiveness and market share in the biopharmaceutical industry.
See More
Aurinia Pharmaceuticals Q1 Earnings Exceed Expectations
- Earnings Beat: Aurinia Pharmaceuticals reported a Q1 GAAP EPS of $0.25, exceeding expectations by $0.05, indicating a strengthening profitability that may boost investor confidence.
- Significant Revenue Growth: The company achieved revenue of $77.7 million in Q1, a 24.4% year-over-year increase, surpassing expectations by $0.72 million, reflecting strong market performance and rising product demand.
- Strong LUPKYNIS Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS reached $73.6 million, up 23% from $60.0 million in the same period of 2025, indicating increasing market acceptance of the drug for active lupus nephritis treatment.
- Optimistic Outlook: Aurinia reiterated its guidance for total revenue in 2026 to be between $315 million and $325 million, representing an 11% to 15% increase compared to 2025, demonstrating confidence in future growth with net product sales projected at $305 million to $315 million, up 12% to 16%.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Aurinia Acquires Kezar Life Sciences for $6.955 per Share
- Acquisition Details: Aurinia Pharmaceuticals is acquiring Kezar Life Sciences for $6.955 in cash per share, along with a contingent value right, aiming to enhance its product line and market competitiveness through the integration of Kezar's assets.
- Clinical Development Potential: Kezar's zetomipzomib, a potential first-in-class immunoproteasome inhibitor currently in phase 2 trials, has shown durable steroid-sparing remissions, which could provide Aurinia with new treatment options in the autoimmune hepatitis space.
- Financial Benefit Expectations: The transaction also includes potential proceeds from Kezar's collaboration with Everest Medicines and its sale of projects to Enodia Therapeutics, which is expected to generate additional cash flow for Aurinia, further supporting its R&D and market expansion.
- Strategic Development Direction: Aurinia targets LUPKYNIS sales of $305M to $315M for 2026, and the acquisition of Kezar will aid its long-term strategic positioning in the autoimmune disease sector, enhancing its market share.
See More
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences in $6.955 Per Share Deal
- Merger Agreement: Aurinia Pharmaceuticals has entered into a definitive merger agreement to acquire Kezar Life Sciences for $6.955 per share in cash, along with a non-transferable contingent value right (CVR), which is expected to enhance Aurinia's market position in autoimmune disease treatments.
- Positive Stock Reaction: Following the announcement, Kezar's stock surged by 19.02% to $7.33, indicating strong market confidence in the transaction and reflecting investor optimism regarding Aurinia's future growth prospects.
- Transaction Details: Aurinia plans to commence a tender offer by April 13, 2026, to acquire all outstanding shares of Kezar, with the transaction expected to close in the second quarter of 2026, ensuring that all remaining shares not tendered will receive the same cash and CVR consideration.
- Product Development Outlook: Kezar's lead candidate, Zetomipzomib, has shown clinically meaningful results in treating autoimmune hepatitis and has had positive interactions with the FDA, which may accelerate its development; Aurinia's successful track record in this area positions it well to advance this novel therapeutic agent.
See More
Aurinia Reports 23% Revenue Growth in Q1
- Revenue Growth Highlight: Aurinia reported first-quarter revenue of $77.7 million, a 24% year-over-year increase that surpassed Wall Street's expectations of $77 million, indicating strong market performance despite a stock price drop due to information scarcity.
- Lupkynis Sales Surge: The 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, was the primary driver of revenue growth, reflecting robust market demand for this critical therapy.
- Leadership Change Impact: Following a significant leadership overhaul in March, with Kevin Tang appointed as CEO, investor unease grew due to the absence of an earnings call and limited updates on clinical trials, resulting in a more than 10% drop in stock price in a single day despite positive earnings.
- Future Outlook: The company reiterated its FY2026 revenue guidance of $315 million to $325 million, representing an 11% to 15% year-over-year growth, demonstrating confidence in future growth prospects despite market volatility.
See More
Aurinia Pharmaceuticals Reports Q1 Earnings Growth
- Earnings Growth: Aurinia Pharmaceuticals reported a first-quarter net income of $34.36 million, translating to an EPS of $0.25, which marks a significant increase from last year's $23.34 million and $0.16 EPS, indicating strong market performance.
- Revenue Increase: The company's revenue for the quarter reached $77.71 million, up 24.4% from $62.47 million last year, driven primarily by increased market acceptance of new products, reinforcing its position in the biopharmaceutical sector.
- Full-Year Guidance: Aurinia has provided a full-year revenue guidance of $315 million to $325 million, reflecting confidence in future market demand and potentially attracting more investor interest.
- Market Reaction: With the improved earnings and positive outlook guidance, Aurinia's stock is likely to gain favor among investors, further enhancing its competitiveness and market share in the biopharmaceutical industry.
See More
Aurinia Pharmaceuticals Q1 Earnings Exceed Expectations
- Earnings Beat: Aurinia Pharmaceuticals reported a Q1 GAAP EPS of $0.25, exceeding expectations by $0.05, indicating a strengthening profitability that may boost investor confidence.
- Significant Revenue Growth: The company achieved revenue of $77.7 million in Q1, a 24.4% year-over-year increase, surpassing expectations by $0.72 million, reflecting strong market performance and rising product demand.
- Strong LUPKYNIS Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS reached $73.6 million, up 23% from $60.0 million in the same period of 2025, indicating increasing market acceptance of the drug for active lupus nephritis treatment.
- Optimistic Outlook: Aurinia reiterated its guidance for total revenue in 2026 to be between $315 million and $325 million, representing an 11% to 15% increase compared to 2025, demonstrating confidence in future growth with net product sales projected at $305 million to $315 million, up 12% to 16%.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Aurinia Acquires Kezar Life Sciences for $6.955 per Share
- Acquisition Details: Aurinia Pharmaceuticals is acquiring Kezar Life Sciences for $6.955 in cash per share, along with a contingent value right, aiming to enhance its product line and market competitiveness through the integration of Kezar's assets.
- Clinical Development Potential: Kezar's zetomipzomib, a potential first-in-class immunoproteasome inhibitor currently in phase 2 trials, has shown durable steroid-sparing remissions, which could provide Aurinia with new treatment options in the autoimmune hepatitis space.
- Financial Benefit Expectations: The transaction also includes potential proceeds from Kezar's collaboration with Everest Medicines and its sale of projects to Enodia Therapeutics, which is expected to generate additional cash flow for Aurinia, further supporting its R&D and market expansion.
- Strategic Development Direction: Aurinia targets LUPKYNIS sales of $305M to $315M for 2026, and the acquisition of Kezar will aid its long-term strategic positioning in the autoimmune disease sector, enhancing its market share.
See More
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences in $6.955 Per Share Deal
- Merger Agreement: Aurinia Pharmaceuticals has entered into a definitive merger agreement to acquire Kezar Life Sciences for $6.955 per share in cash, along with a non-transferable contingent value right (CVR), which is expected to enhance Aurinia's market position in autoimmune disease treatments.
- Positive Stock Reaction: Following the announcement, Kezar's stock surged by 19.02% to $7.33, indicating strong market confidence in the transaction and reflecting investor optimism regarding Aurinia's future growth prospects.
- Transaction Details: Aurinia plans to commence a tender offer by April 13, 2026, to acquire all outstanding shares of Kezar, with the transaction expected to close in the second quarter of 2026, ensuring that all remaining shares not tendered will receive the same cash and CVR consideration.
- Product Development Outlook: Kezar's lead candidate, Zetomipzomib, has shown clinically meaningful results in treating autoimmune hepatitis and has had positive interactions with the FDA, which may accelerate its development; Aurinia's successful track record in this area positions it well to advance this novel therapeutic agent.
See More
